The study showed lower reoperation rates for the Mobi-C and better mean neck disability improvement through four years.
Hyun Bae, MD, medical director and director of spine education at Cedars-Sinai in Los Angeles, presented the data earlier this month at the North American Spine Society annual meeting.
The Mobi-C is the first cervical disc replacement device approved by the FDA for both one- and two-level indications.
More Articles on Devices:
K2M, Amedica Reach European Distribution Agreement for Biomaterial Spinal Fusion Devices
Zimmer Holdings Reports Decreased Earnings, Spine Sales in Q3
15 New Spine, Orthopedic Device Launches & Releases
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
